Skip to main content
OpenTrials
Completed

NCT Number: NCT04522310

ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis

COVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital of Arras, Arras, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any adult patient admitted in the ICU with COVID-19 pneumonia

Exclusion criteria

  • Pregnancy
  • Legal reasons (patients under guardianship, curatorship)
  • Patient's refusal

Treatment and study plan

MR-Pro-ADM

Other

Dosage of MR-pro-ADM

Primary outcomes

  1. Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.

    Time frame: comparison to day 1 and day 3

    Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.

  2. mortality at day 28 and day 90.

    Time frame: admission until day 90

    mortality at day 28 and day 90.

Secondary outcomes

  1. Association between MR-ProADM and mortality at day 28.

    Time frame: admission until day 28

    Association between MR-ProADM and mortality at day 28.

  2. Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28.

    Time frame: admission until day 28

    Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28.

Sponsors and collaborators

Lead sponsor

Centre Hospitalier de Lens

Other

Registry information

Acronym: PAMOCOS

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Aug 21, 2020
Registry last updated
Aug 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.